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Abstract
Background: Prescribing errors at the time of hospital discharge are common and could potentially lead to
avoidable patient harm, especially when they involve insulin, a high-risk medicine widely used for the treatment of
diabetes mellitus. When information regarding insulin therapy is not sufficiently communicated to a patient’s
primary care provider, continuity of care for patients with diabetes may be compromised. The objectives of this
study were to investigate the nature and prevalence of insulin-related medication discrepancies contained in
hospital discharge summaries for patients with diabetes. A further objective was to examine the timeliness and
completeness of relevant information regarding insulin therapy provided on discharge summaries.
Methods: The study was undertaken at a large foundation trust hospital in the North of England, UK. A
retrospective analysis of discharge summaries of all patients who were being treated with insulin and were
included in the 2016 National Inpatient Diabetes Audit was conducted. Insulin regimen information provided on
discharge summaries was scrutinised in light of available medical records pertaining to the admission and current
national recommendations.
Results: Thirty-three (79%) out of the 42 patients included in the study had changes made to their insulin regimen
during hospital admission. Eighteen (43%) patients were identified as having an error or discrepancy relating to
insulin on their discharge summary. A total of 27 insulin errors or discrepancies were identified on discharge, most
commonly involving non-communication of an insulin dose change (n = 8) and wrong insulin device (n = 7).
Seventeen issues relating to completeness of insulin information were identified, including the omission of the
prescribed time of insulin administration (n = 10) and unexplained insulin dose change (n = 4). Two patients who
had insulin-related errors identified on their discharge summaries were readmitted to hospital within 30 days of
discharge due to poor diabetic control.
Conclusions: This small-scale study demonstrates that errors and discrepancies regarding insulin therapy on
discharge persist despite current insulin safety initiatives. Poorly communicated information regarding insulin
therapy may jeopardise optimal glycaemic control and continuity of patient care. Insulin-related information should
be comprehensively documented at the point of discharge. This is to improve communication across the interface
and to minimise risks to patient safety.
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Background
Discharge summary information
A quality discharge process is vital to ensuing patient
safety and continuity of care in the community. On dis-
charge from hospital it is important that general practi-
tioners (GPs, primary care physicians) receive accurate
and timely communication with respect to patients’
medications. This is important in the context to prevent
potentially harmful medication-related errors that could re-
sult in further hospitalisation [1]. Medication errors at the
point of discharge have previously been reported as ‘com-
mon’ [2, 3] and can include unintended omission of medi-
cation, continuation/re-prescribing of an intentionally
stopped medication, or an error in medication dose, fre-
quency or formulation [3–5]. Such errors have been found
to persist post-discharge and pose a greater risk to patient
care than those on identified on admission, [6] potentially
leading to readmission [7, 8]. A United Kingdom (UK) gov-
ernment report highlighted the need for hospitals to im-
prove the information provided about medications on
discharge following findings suggesting that the majority of
medication information on discharge summaries was in-
complete or inaccurate [9]. In 2008, the UK National Pre-
scribing Centre (NPC), specified a minimum dataset of
information to be communicated at all transitions of pa-
tient care. This was to maintain patient safety [10]. Despite
this, one study found that these requirements were consist-
ently not being met in sampled discharge summaries, with
71.7% adhering to the total NPC minimum dataset, 67.2%
adhering to medicine information requirements and less
than half (48.9%) adhering to therapy change information
requirements, with rationale for medication change
amongst the most frequent omissions [11]. Similar rates
(65.5–68%) of poor documentation of medication changes
on electronic discharge summaries have been identified in
other studies conducted in England by Cresswell et al. [12]
and in Ireland by Grimes et al. [13], with higher rates
(80.5%) being reported in Australia by Lehnbom et al. [14].
Callen et al. [4], found similar rates of medication error be-
tween handwritten and electronic discharge summaries
when using systems similar to those reported in this study.
The authors of these studies suggest that input from clinical
pharmacy teams and junior doctor training may hold the
potential to reduce discharge medication errors, as well as
the use of integrated systems within a complete electronic
health record [4, 12–14].
Insulin therapy and hospital discharge
The importance of communicating sufficient informa-
tion pertaining to discharge medication is even more
pertinent when high-risk drugs, capable of causing pa-
tient harm, are involved. Insulin is a high-risk, critical
medicine widely used in the treatment of diabetes melli-
tus [15], where inappropriate use can lead to poor
glycaemic control, patient harm or even death [16, 17].
Anecdotal evidence reported by Leech et al. [18] de-
scribes incidences where GPs were unsure of what dose
of insulin to prescribe after patients were discharged
from hospital because “patients tell [them] completely
different doses to the [discharge] letter” and where dis-
trict nurses find it “really difficult getting details [regard-
ing insulin therapy after discharge] and patients can be
very uncertain.” Upon discharge from hospital the com-
munication must ensure that not only the correct insulin
is prescribed, but that this is supported with sufficient
additional information to prevent consequential patient
harm. Medication errors involving insulin have been
previously reported as occurring at various points
throughout the patient hospital stay, including at the
point of discharge [19, 20]. A large audit of 54 National
Health Service (NHS) trusts found that insulin-related
medication errors were common at the point of pre-
scribing in hospital. The most common error reported
was ‘unclear or missing administration device’, which the
authors comment is particularly problematic at care in-
terfaces, such as discharge from hospital [21].
In 2015, A Canadian study reported improvements in
the quality and value of information communicated
across the interface for patients with diabetes with the
use of a specialised discharge letter template [22]. Dur-
ing the same year, the Joint British Diabetes Society
(JBDS) released guidelines to help healthcare profes-
sionals in secondary care to plan the safe and effective
discharge of adult inpatients with diabetes. Recommen-
dations included the use of a comprehensive checklist to
ensure that adequate information is transferred between
care providers. Data from the 2016 National Inpatient
Diabetes Audit (NaDIA) of England and Wales indi-
cated, however, only 11.5% of sites currently imple-
ment these guidelines, and that the prevalence of
insulin-related medication errors has not decreased
since 2011 [23].
There is a paucity in the literature regarding the na-
ture and prevalence of insulin-related prescribing errors
at the point of discharge. Also there is lack of quality of
insulin information being communicated in hospital dis-
charge summaries, particularly relating to insulin devices
and dose changes [18, 21], and a poor uptake of the
JDBS discharge guidelines [23]. In this context, this
study was planned.
Aims and objectives
The aim of the study was to investigate the nature of
insulin-related prescribing errors and to evaluate the
completeness of relevant information provided on the
discharge summaries of insulin-treated patients with
diabetes. The objectives of this study included:
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 To classify the nature of insulin-related prescribing
errors or discrepancies on discharge summaries
from the hospital.
 To determine the prevalence of insulin-related
prescribing errors or discrepancies on discharge in
the study population.
 To examine the timeliness and completeness of
information related to insulin therapy
communicated to general practitioners on discharge
summaries.
To determine if any of the study population affected
by a prescription error or information discrepancy had a
diabetes- related emergency hospital readmission within
30 days of discharge.
Methods
Study context
The study was undertaken over a 6-week period during
January and February 2017 at a large NHS Foundation
Trust in South Yorkshire, UK, providing local secondary
and specialist tertiary diabetes care. The study site does
not currently employ the use of an integrated electronic
patient record and inpatient prescribing system. In-
patient medical notes, including prescriptions, are docu-
mented on paper and retrospectively uploaded to an
electronic patient record after discharge. All information
communicated on discharge, including the discharge
medication prescription, is however, manually entered
into to an electronic discharge template by prescribers
(via transcription from paper inpatient prescription
charts). Then it is sent to primary care providers (e.g.
GPs) via an online integrated clinical environment (ICE)
system, which is used throughout the local area. This
electronic discharge template contains mandatory fields
that need to be populated before allowing prescribers to
complete the discharge summary, for example ‘follow-up
plans for hospital/community’. An optional section
regarding “medication changes”, where prescribers are
requested to document any intentional changes to medi-
cation made since admission to hospital, is also included.
After the prescriber completes an individual discharge
summary, a clinical pharmacist will electronically verify
the prescription and then the nurse will finalise the
process by completing and printing the discharge sum-
mary (for the patient and their medical records). The
system then automatically sends the document electron-
ically to the respective GP. Completion of all the pro-
cesses is indicated via an icon change on the computer
screen.
Data collection
A retrospective analysis was conducted that included all
patients with insulin-treated diabetes who were receiving
care as inpatients at the study hospital during the 29th
September 2016, who were eligible for inclusion in the
National Diabetes Inpatient Audit (NaDIA) and whose
data was collected for the NaDIA. Patients who were ex-
cluded from the NaDIA (e.g. paediatric patients, patients
on mental health wards, in the emergency department,
day case wards, short-stay units or palliative care units)
or whose data was unable to be retrieved during the
NaDIA (e.g. due to unavailability of patient records)
were therefore not included.
Patients’ medical records were examined by a single
reviewer for the entire inpatient episode that included
the NaDIA collection date (29th September 2016). This
included admission documentation, prescription charts
and electronic discharge summaries. Patients who had
unavailable medical records or who had died during
their inpatient stay were not included in the final ana-
lysis. The data collection sheet was designed to capture
in free-form any noted discrepancies or errors relating
to insulin information and prescription, as well as the
extent of adherence to medication-related discharge rec-
ommendations specified by both the NPC and JBDS (see
Table 1). Where ambiguities in interpretation of infor-
mation contained in medical records arose, a single clin-
ical pharmacist was consulted to clarify and confirm
information at the point of data collection.
Changes to a patient’s insulin regimen were identified
by recording insulin prescription information. This in-
formation included preparation, device, frequency of ad-
ministration, time of administration and number of
units used. These changes were documented on three
occasions throughout the patient stay. These were on
admission, the handwritten prescription on the day of
discharge and on the electronic discharge summary. The
electronic discharge summary’s status was also recorded
in order to indicate if it had been provided to the patient
and sent to the patient’s GP in line with local and na-
tional recommendations.
All data collected as part of the study was anonymised
in order to maintain patient confidentiality. The study
design and data collection method was reviewed and
Table 1 Medicines-related information to be communicated in
discharge summaries according to JBDS and NPC criteria (adapted
from 24,10)
A list of all medicine prescribed for the patient on discharge from
hospital (and not just those dispensed at the time of discharge)
Dose, frequency, formulation and route of all the medicines listed
Medicine stopped and started, with reasons
Details of increasing, or decreasing dose regimens
This information should be clear, unambiguous and legible and should
be available to the GP as soon as possible.
Patients should be given a copy of their discharge summary (JBDS 2015)
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endorsed by a specialist panel as part of the hospital’s
clinical effectiveness unit.
Insulin prescription errors, discrepancies and
completeness of information issues
In order to investigate and classify the nature of insulin-
related errors or discrepancies, data was collected re-
garding any changes that have been made to the insulin
regimen during the inpatient stay, whether an error or
discrepancy had occurred at the point of discharge and
the nature of any such errors or discrepancies. For the
purposes of this study, an error was defined as erroneous
or incomplete documentation of insulin preparation,
device, route, dose (number of units) or frequency tran-
scribed onto the discharge summary when compared
with the inpatient prescription on the day of discharge
[19]. A discrepancy was defined as a failure to communi-
cate any changes made to insulin therapy in the desig-
nated “medication changes” section of the discharge
prescription (e.g. where an insulin dose had changed
since admission but no indication of the intention of this
was documented) [24, 25]. A lack of explicit documenta-
tion of insulin regimen changes could cause confusion
and uncertainty regarding the accuracy of the discharge
information in primary care, and could result in conse-
quential prescribing errors or suboptimal glycaemic con-
trol in primary care.
Examination of completeness of information provided
on discharge summaries involved studying the whole
discharge summary in order to identify any omissions of
relevant insulin information to be communicated to the
GP. A ‘completeness of information issue’ was identified
when an important piece of insulin information was
omitted from the discharge summary. This may include,
for example, failure to record a time for insulin adminis-
tration (e.g. stating ‘daily’ rather than ‘every morning’) or
an explanation for any intentional change in insulin
regimen (e.g. dose decreased due to persistent
hypoglycaemia). Although these issues are arguably less
likely to cause direct harm to a patient (e.g. compared to
a prescription error), they may lead to interface issues
and difficulties in providing continuity of care to patients
in the community. For example, in the case of missing
or unclear information provision, primary care providers
may need to contact the hospital in order to clarify im-
portant information pertaining to a patient’s insulin
therapy.
Data analysis
Information regarding patients’ insulin regimens and any
errors, discrepancies or issues was collected in free-form.
Errors, discrepancies and completeness of information is-
sues were then classified during thematic analysis. Data
analysis was carried out using Microsoft Excel 2016 and
IBM SPSS Statistics v22. Data for patients who had died
during inpatient stay, or those for whom a complete set of
medical notes could not be obtained, were removed before
final analysis.
Results
Study population
A total of 72 patients who were prescribed insulin for a
diabetes diagnosis were included in the National Dia-
betes Inpatient Audit data collection at the trust, and
were therefore eligible for inclusion in the study. Six pa-
tients had died during their inpatient stay and a further
24 patients were excluded due to a lack of availability of
medical notes during data collection. A total of 42
patients were therefore included in the final study. Of
the included patients; 64% (n = 27) had type 2 diabetes,
29% (n = 12) had type 1 diabetes and 7% (n = 3) had
cystic fibrosis-related diabetes. An average of 1.1 insulin
preparations were prescribed per patient both on admis-
sion and discharge. Table 2 shows the proportion of pa-
tients who were prescribed different numbers of insulin
preparations on admission and discharge, illustrating
that most patients included in the study were using a
single insulin preparation.
Thirty-eight (90%) of patients had undergone a medi-
cines reconciliation process on admission to hospital by
a pharmacy team member. Thirty-three out of 42 pa-
tients (79%) had changes to their insulin regimen made
during their inpatient stay. This included the initiation
and/or discontinuation of insulin therapy, insulin dose
changes and insulin preparation/brand.
The majority of patients were inpatients in care of the
elderly (COTE) wards (23.8%), followed by; admissions
wards (19%), surgical (16.7%), cardiology (14.3%), diabetes
and endocrine (11.9%), cystic fibrosis (7.1%), orthopaedics
(4.8%) and respiratory (2.4%) wards.
The length of inpatient stay ranged from 3 to 228 days,
with the mean duration of stay being 36 days (SD = 40).
Nature and prevalence of insulin-related prescribing
errors or discrepancies on discharge
Eighteen (43%) patients had an error or discrepancy re-
lating to insulin on their discharge summary, 11 (61%)
of whom had type 2 diabetes, 6 (33%) had type 1 dia-
betes and 1 (6%) had cystic fibrosis-related diabetes. All
Table 2 Numbers of insulin preparations per patient on
admission and discharge
Number of insulin preparations
prescribed per patient
Numbers of
patients on
admission
Numbers of
patients on
discharge
n = 0 6 (14%) 5 (12%)
n = 1 27 (64%) 29 (69%)
n = 2 9 (21%) 8 (19%)
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patients who had a change made to their insulin during
admission had at least one error, discrepancy or
completeness of information issue identified on their
discharge prescription. A total of 27 errors or discrepan-
cies were identified across the 42 patients included in
the study, giving a frequency of 0.6 per patient. The
most frequent error or discrepancy identified was the
failure to communicate an intentional insulin dose
change in the “medication changes” section (Fig. 1). The
greatest number of errors or discrepancies identified for
one patient was 4, which included the failure to docu-
ment the discontinuation of one insulin preparation, the
initiation of another insulin preparation and the dose
change for another insulin preparation under the “medi-
cation changes” section, and not including the dose of
an insulin preparation on the discharge prescription.
Most errors had occurred on discharge from COTE
(26%, n = 7) and surgical wards (26%, n = 7), followed
by; cardiology (19%, n = 5), diabetes and endocrine
(15%, n = 4), admissions (7%, n = 2) and cystic fibrosis
(7%, n = 2) wards.
Timeliness and completeness of information
communicated to general practitioners
All discharge summaries analysed (100%) were of the
same electronic format and had been marked as sent to
the GP via the ICE interface. As the system automatic-
ally prints a copy of the discharge summary for the pa-
tient upon transmission to the GP, it can be assumed
that 100% of patients also received a paper copy of the
same discharge summary as per hospital procedure, al-
though this could not be determined definitively from
this study.
A total of 17 (40%) patients had discharge summaries
containing incomplete insulin information (henceforth
referred to as ‘completeness of information issues’). A
total of 17 completeness of information issues were
identified in total, giving a frequency of 0.4 per patient.
The nature and prevalence of these issues is shown in
Fig. 2, with failure to specify a time for insulin adminis-
tration being the most prevalent.
Completeness of information issues had occurred on
three occasions on discharge summaries produced from
COTE, cardiology, admissions and diabetes and endo-
crine wards (18% each); on two occasions by both ortho-
paedic and cystic fibrosis wards (12% each) and once
from surgical wards (6%).
Readmission
Twelve (29%) patients were readmitted back to the hos-
pital trust within 30 days of the recorded discharge date
with an emergency, of which three (25%) were due to a
diabetes-related reason. Two (66%) of these three
patients had a discrepancy identified on the discharge
summary written prior to readmission. The first patient
was readmitted due to ‘poor diabetic control’ who did
not have their insulin dose change explicitly written on
their discharge summary from a COTE ward. The sec-
ond patient was readmitted for hyperglycaemia, who also
did not have their insulin dose change explicitly commu-
nicated on their last discharge summary from a diabetes
and endocrine ward.
Discussion
This study provides a unique insight into the current
situation regarding the quality and accuracy of insulin-
related information documented for patients with
diabetes who are being discharged from hospital. Initial
results may help inform quality improvement initiatives
to reduce the risk to patients and improve the safe usage
Fig. 1 The nature and prevalence of insulin errors or discrepancies identified at discharge
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of insulin. Findings suggest that electronic discharge
summaries can provide timely information to primary
care providers and patients. Important information
contained in discharge summaries is, however, often in-
complete and sometimes erroneous, with the potential
implication for compromised continuity of care and
patient safety.
Nature and prevalence of insulin-related prescribing er-
rors or discrepancies on discharge
The majority of patients had changes made to their insu-
lin therapy during hospital stay. All patients with
changes had an error or discrepancy identified on their
discharge summary. This suggests that further progress
is required to ensure consistent quality of communica-
tion on discharge for patients with insulin-treated dia-
betes, with particular care being paid to those where a
change has occurred. The proportion of total patient
discharge summaries with identified insulin-related pre-
scribing errors is similar to that found for inpatients by
the hospital trust’s NaDIA in 2016 [23], suggesting that
errors can easily be continued through to discharge at
similar rates during inpatient stay.
The most common type of insulin error or discrepancy
identified on discharge was a failure to communicate an
insulin dose change. This result differs from studies that
cite drug omission from discharge prescriptions as the
most frequent error type [3–5]. These studies do not
focus on patients with insulin-treated diabetes specific-
ally, however, and due to the high-risk and critical na-
ture of insulin, it could be less likely to be omitted
altogether from the discharge prescription (especially
when medicines reconciliation are completed on admis-
sion was the case for the majority of patients in this
study) compared to other medication. The results, do,
however, support the findings of studies that report a
high proportion of discharge summaries excluding
medication changes [11, 12]. Failure to explain or con-
firm an insulin dose change on discharge may not be as
serious as a dosing prescribing error, but the lack of
clarity in communication can risk the patient, carer or
primary care provider administering an erroneous dose
(e.g. that prescribed before or during admission) and
therefore risk optimal glycaemic control. The need for
GPs or other community healthcare professionals to
clarify any changes made may result in a disruption to
continuity of care and risk patient safety (especially
when a dose change cannot be promptly clarified, e.g. by
a carer administering insulin to patients in their home
immediately after discharge). This can also result in inef-
ficiencies due to an avoidable increased workload. Rec-
ommendations for future policy and practice could
include prescriber review of insulin therapy at the point
of discharge prescription writing (e.g. by comparison
with medicines reconciliation documentation), ensuring
that details of any intentional changes being made are
explained on the discharge summary.
The second most frequent insulin error or discrepancy
identified at discharge was prescription of the wrong ad-
ministration device on the discharge summary. Other
studies have found that increasing diversity in the types
of insulin and variety of devices available in the UK may
cause confusion when prescribing insulin and may result
in the incorrect device being prescribed [26]. This find-
ing reflects the results of a large audit conducted by East
and South East England Specialist Pharmacy Services
[21], which found the most common inpatient insulin
prescribing error was selection of the wrong administra-
tion device. The input of clinical pharmacy services
throughout admission and again on discharge may ac-
count for the decreased prevalence of this error identi-
fied in this study, which looked at discharge summaries
after pharmacist review. Interestingly, the NaDIA [23]
does not include administration device error as a
Fig. 2 The nature and prevalence of completeness of information issues identified on discharge summaries
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medication error, despite the potentially harmful conse-
quences of prescribing and dispensing the wrong device,
which could result in patients being unable to adminis-
ter their insulin. For example, erroneously prescribing
and dispensing insulin cartridges instead of a disposable
pen or a vial could lead to an inability to administer in-
sulin. Another example is dangerous administration
practices such as drawing insulin out of a cartridge with
a syringe [16, 27].
The majority of insulin errors or discrepancies were in
patients discharged from care of the elderly (COTE) and
surgical wards. The result for COTE wards was expected
as they contained the majority of patients. Patients on
surgical wards, however, were more likely to experience
an insulin-related error or discrepancy. Furthermore, the
surgical wards included in this study had the greatest
range of insulin errors or discrepancies identified on dis-
charge. The higher frequency of insulin-related errors on
discharge summaries from surgical specialities somewhat
contrasts national data that shows no difference between
insulin-related errors on medical and surgical wards,
despite a higher incidence of medicines management
and general diabetes medication prescribing errors [23].
Patients with diabetes discharged from surgical wards
are possibly less likely to have a diabetes-related admis-
sion, with a consequential decrease in likelihood of any
specialist diabetes team involvement in their care, and are
also more likely to have their discharge summaries written
by doctors working in surgical specialists who may have
less prescribing support from senior colleagues [28].
Timeliness and completeness of information
communicated to general practitioners
As all 42 discharge summaries were marked as sent
to the general practitioner and patient, this study re-
ports 100% adherence to the recommendation that
“information should be made available to the GP as
soon as possible” [10] and “patients should be given a
copy of their discharge summary” [24] – see Table 1.
The use of an electronic system to ensure discharge
summaries are promptly sent to general practitioners
and provided for patients has previously been shown
to aid the timeliness of communication to GPs com-
pared with other methods, such as postal or manual
delivery of paper documents [29, 30]. It is therefore
very likely that the electronic discharge template con-
tributed to the 100% compliance with this standard
found in this study. Timeliness of information com-
munication regarding medication is particularly im-
portant when critical medicines such as insulin are
involved, especially when a third party is responsible
for the administration of insulin to patients (e.g.
where patients rely on domiciliary carers to adminis-
ter insulin doses) [25].
Completeness of information issues were fewer in
number than prescribing errors or discrepancies, but
may also lead to lack of clarity and problem develop-
ment at the interface of care. The most common
completeness of information issue identified was non-
specification of the time of insulin dose. This finding
supports that of the North-East RISK project, which
established that many of discharge prescriptions did not
contain information relating to the time of insulin ad-
ministration [18]. This particular completeness of infor-
mation issue was found to have been distributed fairly
evenly across the clinical areas included in the study. As
the inclusion of details regarding time of insulin dose is
not a mandatory requirement on the electronic
discharge system at the study hospital, the relative
prevalence of this issue may be explained. Introduction
of electronic prescribing systems with details of adminis-
tration time could aid this issue in future by pre-
populating the prescription with this information.
Readmission
Emergency hospital readmission within 30 days of
discharge is widely used as a quality indicator for the
success of hospitals in helping people to recover [31].
Hospital readmission can lead to the increased expend-
iture of secondary care providers and have a negative
impact on patient health [32]. The readmission of the
two patients in this study for a diabetes-related problem
and with insulin-related discrepancies on their discharge
summary could not be definitively attributed to the insu-
lin issues in question, due to the complexities and con-
tributing factors pertaining to hospital readmission. This
is reinforced by a study conducted by Rubin in 2015,
which concluded that factors such as socio-economic
status, race and ethnicity also influenced the incidence
of readmission [32]. Although a definitive link cannot be
established between discharge summary quality and re-
admission in this study, other studies have reported that
communication gaps with respect to medication changes
may contribute to preventable hospital readmissions [33].
Strengths and limitations
This study describes an accessible means of obtaining
meaningful data with respect to discharge summary in-
formation for patients who use insulin to manage their
diabetes. The results provide an insight into the nature
and prevalence of insulin-related prescribing errors and
discrepancies as well as the completeness of information
provided on transfer of care from hospital to community
sectors. Use of the NaDIA data collected by the trust
enabled a wide-variety of patient information to be
analysed and offered a convenient sampling method that
could be replicated in other hospitals elsewhere in the
UK, or further afield by use of similar national audit data
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collections. Limitations of the study included the small
sample size and the large proportion of patients who
were not included on account of unavailable patient
medication records at the time of data collection. We
anticipate that complete data capture would be less
problematic for hospital trusts who make use of a fully
integrated electronic patient medical record and
prescribing system, unlike the study hospital who still
employ the use of paper documentation for inpatient
medical records and prescriptions.
Although timeliness of transfer of discharge summar-
ies could be studied from the hospital, we did not meas-
ure the time lapse in GP receipt and processing of
discharge summaries in primary care. Further work that
examined primary care healthcare professionals’ percep-
tions of timeliness and completeness of information
would further complement this study’s findings.
Furthermore, as data was collected retrospectively,
clinical pharmacy intervention at the point of verifica-
tion of discharge prescriptions was not examined. This
meant that only discharge summaries that had been
authorised by a pharmacist, and therefore transferred to
the general practitioner, were studied. Although this pro-
vides an accurate reflection of the quality of documenta-
tion transferred to the GP, prospective examination of
discharge summaries before clinical pharmacy interven-
tion may provide a more accurate, less conservative,
picture of prescriber error and information discrepancy
rate on discharge.
Conclusions
This study highlights the current status with respect to
quality of insulin-related information communicated at
the point of discharge, and the types of problems that
may occur on the interface for patients with insulin-
treated diabetes. We conclude that the use of electronic
discharge templates can provide a timely method for
communicating important insulin information to GPs
when transferred locally via an integrated system. The
study concludes that the insulin information provided
on discharge summaries is however are often incomplete
and sometimes erroneous, particularly in relation to in-
sulin administration device, details of dose changes and
time of administration. Such errors and omissions in in-
formation have the potential to contribute to continued
insulin-related medication errors in the community and
possibly even readmission to hospital.
Further research
Further research into this area is required to develop
evidence-based initiatives both locally and nationally that
incorporate both NPC and JBDS guidelines for this par-
ticular patient group. Triangulation of data with qualita-
tive studies concerning discharge summary generation,
content, verification and processing (e.g. in primary care)
for this particular patient group would further enable
strategies to be developed to improve patient safety and
continuity of care for patients with diabetes using
insulin.
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